The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Swiss Biotech Report 2026: Strong performance with new records in revenues and investments in privately funded companies

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

Security alerts: Fraudulent emails impersonating the Swiss Biotech Association

We track and escalate fraud campaigns that target Swiss Biotech Association members and Swiss Biotech Day participants. Current campaigns are listed in the box below and updated as new ones appear. The guidance applies to all of them. Please read it carefully and share it within your organization.
September 7, 2026

Helsinn Healthcare & InVirtuoLabs: Collaboration in AI-driven drug discovery

Helsinn Healthcare SA (Helsinn), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based drug discovery company specializing in AI-powered generative chemistry, today announced a strategic collaboration to discover and develop novel small-molecule therapeutics.
February 25, 2026

SOTIO: First patient dosed in colorectal cancer trial

SOTIO Biotech today announced that the first participant has been dosed in its Phase 1/2 CADENCIA-01 clinical trial of SOT109 in colorectal cancer. SOT109 is a potentially best-in-class antibody-drug conjugate exploiting the highly promising target of CDH17 for the treatment of CRC and other gastrointestinal cancers. As the only CDH17-targeting ADC that has been granted U.S. FDA Fast Track Designa
September 9, 2026

Pharvaris: Positive pivotal data in hereditary angioedema prophylaxis

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 All secondary efficacy endpoints met with statistical significance Well-tolerated safety profile of deucrictibant XR demonstrated
September 8, 2026

NovaGo Therapeutics: USD 30 million to advance spinal cord injury study

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury — Round Led by Neurimmune and Pureos, with Participation from Existing and New Investors, Complemented by Non-Dilutive Funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation
September 2, 2026